GlobeNewswire Inc | Nov 4, 2020 08:00AM EST

November 04, 2020

CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Wednesday, November 11, at 11:00 a.m. ET.

A live webcast of the presentation will be available on the Investors & Media section of Mersanas website at www.mersana.com. An archived replay will be available for approximately 90 days following the presentation.

AboutMersana TherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersanas lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersanas second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersanas customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Companys early stage programs include a B7-H4 targeting ADC, as well as a STING agonist ADC developed using the Companys Immunosynthen platform. In addition, multiple partners are using Mersanas Dolaflexin platform to advance their ADC pipelines.

Contact

Investor & Media ContactSarah Carmody617-844-8577scarmody@mersana.com